Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D’Haens(Amsterdam University Medical Centers), Marc Ferrante(Universitair Ziekenhuis Leuven), Remo Panaccione(University of Calgary), Kori Wallace(AbbVie (United States)), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Peter Bossuyt(Imelda Hospital), W. Rachel Duan(AbbVie (United States)), Kristina Kligys(AbbVie (United States)), Alexandra Song(AbbVie (United States)), William J. Sandborn(University of San Diego), Valerie Pivorunas(AbbVie (United States)), Tadakazu Hisamatsu(Kyorin University), Anne Robinson(AbbVie (United States)), Julián Panés(Hospital Clínic de Barcelona), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Silvio Danese(IRCCS Ospedale San Raffaele), Brian G. Feagan(Western University), David T. Rubin(University of California System), Jasmina Kalabic(AbbVie (Germany)), James O. Lindsay(Barts Health NHS Trust), Edward V. Loftus(Mayo Clinic), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Yinuo Pang(AbbVie (United States)), Bidan Huang(AbbVie (United States)), Zhihua Ran(Shanghai Jiao Tong University), Sofie Berg(AbbVie (United States)), Xiaomei Liao(AbbVie (United States)), Filip Baert(AZ Delta), Ezequiel Neimark(Brown University), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Allen Lim(University of Alberta)
The Lancet
May 1, 2022
Cited by 383


Related Papers